{"schema_version":"secwatch.filing_event.v1","accession":"0001579428-25-000007","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.408833+00:00","generated_at":"2026-05-17T11:08:52.700707+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axsome receives ANDA Paragraph IV notice from Apotex for generic Symbravo","bullets":["Apotex filed an ANDA seeking FDA approval to market a generic version of Symbravo (meloxicam-rizatriptan benzoate).","Paragraph IV certification notice received August 19, 2025; Axsame plans to respond in due course.","If Axsame sues within 45 days, a 30-month stay could delay generic approval.","Generic competition threatens Symbravo revenue, which is Axsome's key commercial product."],"urls":{"canonical":"https://secwatch.observer/filing/0001579428-25-000007","json":"https://secwatch.observer/filing/0001579428-25-000007.json","markdown":"https://secwatch.observer/filing/0001579428-25-000007.md","text":"https://secwatch.observer/filing/0001579428-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000157942825000007/0001579428-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000157942825000007/axsm-20250819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:08:52.700707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}